Video Latest - ecancer

Nivolumab shows early promise in Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA

7 Dec 2014

Blinatumomab demonstrates significant clinical activity in residual ALL

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

7 Dec 2014

New immunotherapy compound effective, safe in ALL patients with minimal residual disease

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

7 Dec 2014

T cell therapy leading to prolonged remission for children with aggressive leukaemia

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

7 Dec 2014

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

7 Dec 2014

ASH 2014: Expert discussion on the latest in AML

Prof Alan Burnett and Prof Sergio Amadori

7 Dec 2014

Comment: Blinatumomab for acute lymphocytic leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

7 Dec 2014

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

Dr Catherine Bollard - George Washington University, Washington, USA

7 Dec 2014

ASH 2014: Expert discussion on the latest in CLL

Prof John Gribben and Prof Stephan Stilgenbauer

7 Dec 2014

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma

Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA

7 Dec 2014

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Dr Thomas Martin, MD, University of California, San Francisco, USA

7 Dec 2014

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study

Dr Thomas Martin, MD, University of California, San Francisco, USA

7 Dec 2014

Video